The journal retracts the article “Activating SIRT-1 Signalling with the Mitochondrial-CoQ10 Activator Solanesol Improves Neurobehavioral and Neurochemical Defects in Ouabain-Induced Experimental Model of Bipolar Disorder” [1] cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of images presented in this publication [1].
Adhering to our standard procedure, the Editorial Office and Editorial Board carried out an investigation that identified partial duplication between sub-images of Figure 12 published in [1], presenting different experimental conditions. While the authors collaborated within this process, the Editorial Board has lost confidence in the reliability of the findings and has decided to retract this publication, as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30).
This retraction was approved by the Editor-in-Chief of the journal Pharmaceuticals.
The authors disagree with this decision.
Reference
- Rajkhowa, B.; Mehan, S.; Sethi, P.; Prajapati, A.; Suri, M.; Kumar, S.; Bhalla, S.; Narula, A.S.; Alshammari, A.; Alharbi, M.; et al. RETRACTED: Activating SIRT-1 Signalling with the Mitochondrial-CoQ10 Activator Solanesol Improves Neurobehavioral and Neurochemical Defects in Ouabain-Induced Experimental Model of Bipolar Disorder. Pharmaceuticals 2022, 15, 959. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).